Test Price
2,800 AED✅ Home Collection Available
CDHR1 Gene Cone-Rod Dystrophy Type 15 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 certified processing (Cert: INT/EGQ/2509DA/3139) and Next-Generation Sequencing at clinical-grade depth.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection across all Emirates (daily 8 AM – 11 PM).
- Instant Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by our Consultant Medical Genetics team.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – pre-approval in minutes.
Test Overview & Methodology
The CDHR1 Gene Cone-Rod Dystrophy Type 15 Genetic Test detects pathogenic variants in the CDHR1 gene associated with autosomal recessive cone-rod dystrophy type 15. This targeted Next-Generation Sequencing assay delivers high-resolution molecular analysis to confirm clinical diagnosis and guide ophthalmologic management, genetic counselling, and family planning under DHA precision-medicine standards.
| Parameter | Our Test (ISO 9001 Certified) | Closest Alternative |
|---|---|---|
| Precision / Method | NGS Targeted Gene Sequencing (Illumina NovaSeq; 100% CDHR1 coding region) | Broad retinal dystrophy panel (often superficial coverage) |
| Turnaround Speed | 3–4 Weeks (expedited options available) | 6–10 Weeks |
| Pre-test Genetic Counselling | Included (pedigree drawing, DHA-aligned consent) | Often not provided |
| Post-test Clinical Interpretation | Telephonic session with Consultant Medical Genetics | Written report only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA Registration ID: 9294403): "Cone-rod dystrophy type 15 is a progressive retinal degeneration that demands molecular confirmation to differentiate it from other inherited retinal disorders. Genetic test results must be correlated with clinical findings and electrophysiology. This NGS test provides the clarity needed for accurate diagnosis and timely intervention, enabling precise genetic counselling and informed family planning decisions."
Medication Advisory
Do not discontinue any prescribed medication without consulting your treating ophthalmologist. Genetic test results complement ongoing clinical care and should never replace regular eye examinations or systemic management.
Safety Exclusion Criteria & Emergency Red Flags
- Cannot perform home collection if patient is hemodynamically unstable or requires continuous monitoring.
- Severe needle phobia with history of vasovagal syncope – hospital-based collection mandatory.
- If the patient has acute eye pain, sudden vision loss, or retinal detachment signs, go directly to ER; delay genetic testing.
- Minors (under 18 years) require legal guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. How accurate is the CDHR1 gene test for diagnosing cone-rod dystrophy type 15?
The test delivers over 99.9% analytical sensitivity and specificity for single nucleotide variants and small copy number changes in the CDHR1 gene when performed on a high-quality DNA sample, giving you a near-certain molecular diagnosis as the foundation for genetic counselling and tailored ophthalmology follow-up.
2. Can the test be performed on children in the UAE and what consent is required?
Yes, the test can be performed on minors provided a written consent is obtained from the legal guardian in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. A pre-test genetic counselling session is conducted to review family history and assess the clinical indication before sample collection.
3. What does the turnaround time of 3–4 weeks involve and can I get an interpretation call?
Your sample is sequenced, bioinformatically analyzed, and clinically curated by a team of molecular geneticists; after the report is issued, you receive a complimentary 20-minute telephonic post-test clinical guidance session to explain the findings, inheritance pattern, and next steps, all within the total 3–4 week workflow.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This test is processed at a DHA-licensed facility (License No. 1143) and adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All personal genomic data is stored, processed, and destroyed in compliance with UAE PDPL. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 Certification: INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | CDHR1 Gene Cone-Rod Dystrophy Type 15 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) – Targeted Gene Sequencing on Illumina NovaSeq |
| ICD-10-CM Code | H35.52 (Cone-rod dystrophy) |
| LOINC Code | 94835-9 (Inherited retinal disease targeted mutation analysis panel) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians